SCHEMBL26646908

SCHEMBL26646908

CCOc1cc(S(C)(=O)=O)cnc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR8 Q9NR97 1/20 0.41
▸ RIPK2 O43353 2/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ FYN P06241 3/20 0.39
▸ KCNH2 Q12809 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ MAP4K4 O95819 2/20 0.38
▸ MINK1 Q8N4C8 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TNIK Q9UKE5 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ NOD2 Q9HC29 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26646997 0.87 TLR8 (0.41) TLR8CA12CA1CA2CA9
SCHEMBL26646776 0.83 FYN (0.50) RIPK2FYNKCNH2MAP4K4MINK1
SCHEMBL30068268 0.83 FYN (0.50) RIPK2FYNKCNH2MAP4K4MINK1
SCHEMBL17177772 0.81 ALDH1A1 (0.38) CA12CA1CA2CA9CA14
SCHEMBL17196389 0.80 HTT (0.37) CA12CA1CA2CA9CA14
SCHEMBL17173655 0.78 HTT (0.38) CA12CA1CA2CA9CA14
SCHEMBL18811523 0.75 CA12 (0.36) CA12CA1CA2CA9CA14
SCHEMBL26647136 0.75 ALDH1A1 (0.58) CA12CA1CA2CA9HTT
SCHEMBL913896 0.74 MAP4K4 (0.43) FYNKCNH2MAP4K4MINK1TNIK
SCHEMBL30829003 0.73 FYN (0.39) RIPK2FYNHTTMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 — — US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 — — US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 — — US disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 — — CN disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 — — EP disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
WO-2022240876-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2022-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 TLR8 4015/4885RIPK2 593/4885CA12 4824/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 TLR8 4015/4885RIPK2 593/4885CA12 4824/4885
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 TLR8 4015/4885RIPK2 593/4885CA12 4824/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 TLR8 4015/4885RIPK2 593/4885CA12 4824/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 TLR8 3991/4885RIPK2 583/4885CA12 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback